Efficacy and safety of ezetimibe co‐administered with simvastatin in thiazolidinedione‐treated type 2 diabetic patients

Gaudiani, Linda; Lewin, Andrew; Meneghini, Luigi; Perevozskaya, Inna; Plotkin, D.; Mitchel, Yale; Shah, Sukrut

doi:10.1111/j.1463-1326.2004.00420.x

Cited by 67 publications

(46 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is in agreement with the findings of Gaudiani et al [4], showed that despite the absolute lower values of hs-CRP in the statin plus ezetimibe group, there were no significant variations, neither for hs-CRP, nor for fibrinogen. On contrary, another study [5] showed that hs-CRP, was reduced by 18.2% with simvastatin monotherapy and 34.8% with the co administration of ezetimibe.…”

supporting

confidence: 93%

The impact of ezetimibe and high-dose of statin treatment on LDL levels in patients with heterozygous familial hypercholesterolemia

Pitsavos¹,

Skoumas²,

Tousoulis³

et al. 2009

International Journal of Cardiology

View full text Add to dashboard Cite

supporting

confidence: 93%

The impact of ezetimibe and high-dose of statin treatment on LDL levels in patients with heterozygous familial hypercholesterolemia

Pitsavos¹,

Skoumas²,

Tousoulis³

et al. 2009

International Journal of Cardiology

View full text Add to dashboard Cite

“…This finding indicates the treatment effects were similar in direction to the overall study results and consistently favored EZE/SIMVA therapy even when compared with the highest-potency statin regimens (that is, atorvastatin 40 and 80 mg; rosuvastatin 20 and 40 mg, and SIMVA 80 mg). In several prior studies conducted in patients already taking statin therapy but not at their LDL-C goal, adding EZE was shown to be more effective at lowering LDL-C compared with doubling the statin dose [28,29,30]. …”

Section: Discussionmentioning

confidence: 99%

Efficacy of Ezetimibe/Simvastatin 10/40 mg Compared to Doubling the Dose of Low-, Medium- and High-Potency Statin Monotherapy in Patients with a Recent Coronary Event

Brudi

Reckless²,

Henry³

et al. 2008

Cardiology

View full text Add to dashboard Cite

Objective: The aim of the study was to compare the efficacy/safety of doubling the dose of low-, medium- and high-potency statins on lipids/lipoproteins versus ezetimibe/simvastatin (EZE/SIMVA) 10/40 mg in patients with a recent coronary event. Methods: In this open-label study, patients were stratified by baseline statin therapy (low, medium and high potency) and randomized equally to statin dose doubling or EZE/SIMVA 10/40 mg for 12 weeks. Primary analysis concerned change in low-density lipoprotein cholesterol for the whole population. Treatment-by-stratum interaction evaluated the consistency of treatment effect across statin potency strata. Post hoc analysis of between-group efficacy within strata was performed using ANCOVA. Results: Within each stratum, EZE/SIMVA produced significantly greater reductions in low-density lipoprotein cholesterol, total cholesterol, apolipoprotein B and non-high-density lipoprotein cholesterol (HDL-C) compared to statin doubling. Numerical trends toward smaller between-group reductions were observed with higher-potency statins and reached statistical significance for apolipoprotein B and non-HDL-C. No significant between-group differences in HDL-C and C-reactive protein were observed within each stratum. EZE/SIMVA produced larger reductions in triglycerides versus low-potency statin, whereas it was similarly effective compared with intermediate-/high-potency statins. The safety/tolerability profiles of the treatments were similar across the strata. Conclusions: EZE/SIMVA 10/40 mg produced greater improvements in lipids with a similar safety profile compared to doubling the dose of low-, medium- and high-potency statins.

show abstract

“…[14][15][16][17][18][19] These significantly greater effects have also been shown with ezetimibe added to the moderate doses of statins compared with doubling the dose of the same statin in moderately-high risk and high-risk CHD patients and in diabetic patients. [20][21][22] This study assessed the lipid-altering efficacy and tolerability of 6 weeks of treatment with ezetimibe/simvastatin 10/20 mg versus doubling the dose of simvastatin to 40 mg in patients with hypercholesterolemia and established CHD who had not achieved the National Cholesterol Education Program Adult Treatment Panel III recommended LDL-C target less than 100 mg/dL while being treated with a daily dose of simvastatin 20 mg.…”

mentioning

confidence: 99%

Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients

Averna

Zaninelli

Grazie

et al. 2010

Journal of Clinical Lipidology

View full text Add to dashboard Cite

BACKGROUND: Reducing low-density lipoprotein cholesterol (LDL-C) is the primary goal of therapy in patients with hypercholesterolemia and coronary heart disease (CHD).METHODS: This double blind placebo-controlled study enrolled patients 18 to 75 years of age with primary hypercholesterolemia and established CHD who were taking a stable daily dose of simvastatin 20 mg. Patients were randomized to ezetimibe/simvastatin 10/20 mg (eze/simva; n 5 56) or simvastatin 40 mg (simva; n 5 56) for 6 weeks. Percent change from baseline in LDL-C, total cholesterol, high-density lipoprotein cholesterol (HDL-C), and triglycerides were assessed by use of the Student t test. The percent of patients achieving LDL-C less than 100 mg/dL (,2.6 mmol/L) or less than 80 mg/dL (,2.0 mmol/L) was analyzed via logistic regression with terms for treatment, baseline LDL-C, age, and gender.RESULTS: Baseline characteristics were similar between groups. Treatment with eze/simva combination resulted in significantly greater reductions in LDL-C, total cholesterol, and triglycerides versus doubling the dose of simva to 40 mg (all P , .01). Significantly more patients achieved LDL-C less than 100 mg/dL (,2.6 mmol/L) and less than 80 mg/dL (,2.0 mmol/L) with ezetimibe/simvastatin versus doubling the dose of simva to 40 mg (73.2% vs 25.0%; P , .001) for simvastatin. Changes in HDL-C were similar between treatments. Both treatments were generally well tolerated.CONCLUSION: In high-risk CHD patients with hypercholesterolemia, treatment with eze/simva combination resulted in significantly greater reductions in LDL-C, total cholesterol and triglycerides, as well as greater achievement of recommended LDL-C targets, compared with doubling the simvastatin dose to 40 mg over the 6-week period. (Clinical trial registration number: NCT00423579) Ó

show abstract

Efficacy and safety of ezetimibe co‐administered with simvastatin in thiazolidinedione‐treated type 2 diabetic patients

Abstract: Co-administration of ezetimibe with simvastatin, a dual inhibition treatment strategy targeting both cholesterol synthesis and absorption, is well tolerated and provides greater LDL-C-lowering efficacy than increasing the dose of simvastatin in T2DM patients taking TZDs.

Cited by 67 publications

References 40 publications

The impact of ezetimibe and high-dose of statin treatment on LDL levels in patients with heterozygous familial hypercholesterolemia

The impact of ezetimibe and high-dose of statin treatment on LDL levels in patients with heterozygous familial hypercholesterolemia

Efficacy of Ezetimibe/Simvastatin 10/40 mg Compared to Doubling the Dose of Low-, Medium- and High-Potency Statin Monotherapy in Patients with a Recent Coronary Event

Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients

Contact Info

Product

Resources

About